Naming Diabetics Is What Breaks a Blood Sugar Claim

which sentence did fda quote as drug evidence against lysulin?

FDA quoted Lysulin's own marketing copy: "The combination and high level of these active ingredients have been shown to help maintain healthy A1c blood sugar levels in diabetics and prediabetics." That sentence sits inside the agency's September 7, 2021 warning letter, MARCS-CMS 614517, part of a ten-letter sweep CFSAN sent to supplement sellers the same day. We read the letter as FDA posted it, and the phrase "in diabetics and prediabetics" is the one clause the whole citation turns on.

FDA didn't stop at that line. The same letter cites the blunter claims "Reduces Glucose in the blood stream" and a serving instruction "to reduce blood glucose," plus Instagram hashtags including #type2diabetic and #insulinresistance as evidence of intended use. Hashtags on organic posts counted the same as paid copy — FDA treated the whole footprint as one advertisement.

The mechanism claim was never the problem.

what happens to that sentence when the population clause is removed?

Strip "in diabetics and prediabetics" and the remaining sentence lands close to language FDA itself calls acceptable. FDA's 2000 final rule blesses the structure/function claim "use as part of your diet to help maintain a healthy blood sugar level" as a lawful statement about a normal bodily function, not a disease. Lysulin's sentence, minus the population clause, says almost the same thing: a mechanism claim about blood sugar maintenance, no named condition attached.

That's the whole rewrite, and it's narrower than most compliance checklists admit: keep the ingredient mechanism, drop the audience label, and you've moved from an implied drug claim back toward a structure/function claim. We've laid out the full permitted-versus-forbidden pair, word for word, on the one blood sugar sentence FDA wrote out for you, including the parallel insulin example FDA used to make the same point.

why does naming the audience convert a structure/function claim?

Naming the audience converts the claim because diabetes is a disease under FDA's own definition, and once a sentence attaches to that population, it attaches to the disease itself. 21 CFR 101.93(g)(1) defines disease as damage to a body system "such that it does not function properly," and type 2 diabetes meets that definition without argument. A structure/function claim describes a normal process in a general body; a claim scoped to "diabetics and prediabetics" describes an abnormal one in a named disease population, and FDA reads that scoping as the claim itself, not as harmless targeting information sitting outside the sentence.

FDA's own codified text treats symptom language the same way. Under 21 CFR 101.93, a statement becomes a disease claim if it "has an effect on the characteristic signs or symptoms of a specific disease or class of diseases, using scientific or lay terminology."

This isn't unique to blood sugar, and the underlying test — common versus uncommon, occasional versus chronic — shows up across every niche built on a bodily process instead of a diagnosis. The same qualifying-word logic that keeps a fatigue claim inside the safe harbor governs digestion claims too; see how the line holds for occasional constipation is allowed, with a condition, where a single missing word does the same damage the population clause does here.

does audience targeting on meta create the same evidence trail?

Yes, and it doesn't need a single word of ad copy to do it. Meta's health and wellness advertising standard requires that ads promoting health or weight-related products be targeted to people at least 18 years old, and its personal-attributes rule separately bars implying that a viewer has a specific medical condition — the platform's own contrast is "Depression counseling" against "Depression getting you down? Get help now." If your landing page also names diabetics, you've paired the same two elements FDA cited against Lysulin: a disease population and a mechanism claim, just split across the ad and the page instead of sitting in one sentence.

We checked the same Lysulin letter for how far that evidence trail runs, and FDA states plainly that "the Federal Trade Commission reviewed your websites in August 2021" — the same month, the same properties. Two agencies pulled the same pages independently. Your targeting data, if subpoenaed or screenshotted, sits in the same evidence file as the ad copy and the landing page.

how do quiz funnels and symptom qualifiers reintroduce the problem?

Quiz funnels reintroduce the problem by describing the disease population without naming it, and FDA's rule reaches that too. A qualifier screen asking about fatigue, frequent urination, blurred vision and slow-healing cuts is listing the recognizable symptom cluster for diabetes, and 21 CFR 101.93(g)(2)(ii) makes a signs-and-symptoms claim illegal using "scientific or lay terminology" — lay terminology is exactly what a quiz uses. Most operators treat the qualifier screen as a targeting tool sitting outside the ad and the landing page. FDA's own reading of context says otherwise.

That's the part most media buyers get backward. A blunt population word like "diabetics" is a one-clause fix — delete it. A symptom-based quiz is harder to fix, because the whole funnel's targeting logic depends on describing symptoms the visitor will recognize, and no single word can be struck to cure it.

Symptom lists are population labels in disguise.

which population words are the highest risk in this niche?

The population words carrying the most risk are the ones naming the disease or the prescription drug tied to it. FDA's letter to Hekma Center, LLC quoted a customer testimonial the brand posted itself, in which the company wrote, "We congratulate Mr. Murtada on overcoming diabetes entirely as if it never existed," after describing his reduced Omformin dose. A testimonial can name the population as effectively as body copy — and FDA attributed it to the advertiser regardless of who typed it.

We could not verify a reliable prevalence or age-band figure for diabetic or prediabetic buyers in this niche; CDC and NIDDK pages were unreachable when we checked in early August 2026. Pulling CDC's National Diabetes Statistics Report directly would settle the actual numbers — until then, treat any age-band or prevalence figure circulating among affiliates as unsourced.

how should an offer segment buyers without naming the disease?

An offer should segment buyers by a self-reported number or a normal-range reference, not by a disease label — the same construction FDA blessed for cholesterol claims: language that helps maintain levels already within the normal range. Ask the visitor for a number they already have, a recent fasting reading or a home meter result, and build your funnel around maintaining that number rather than asking whether they've been diagnosed. The diagnosis question is what creates the disease-population evidence trail; the number question doesn't.

Read how the same claim ceiling plays out across the wider vertical in the blood sugar supplement niche: market, buyer, and claim ceiling, which maps where the FDA and FTC lines actually sit before you build a funnel around either one.

Don't assume a refund promise sits outside this problem, either — FDA has cited a brand's own guarantee wording as evidence of a claim in an adjacent niche, a pattern worth checking against your own offer page in your money-back guarantee wording is a claim.

Quick decision checklist

Use this page as a decision aid, not a generic blog post. The practical question is whether the reader needs faster evidence about what is already working in VSL-driven direct response, especially across nutra, supplements, GLP-1, weight loss, blood sugar, and adjacent high-intent health markets.

Daily Intel Service is most relevant when the next decision depends on active market examples: which hook to test, which claim style is risky, which funnel structure is common, which language market is moving, and whether a competitor's creative is likely early, scaling, or already saturated.

• Start with the TL;DR if you need the direct answer.
• Use the table to compare trade-offs quickly.
• Use the FAQ for answer-engine-ready summaries.
• Use the CTA when the decision requires live VSL and ad examples instead of theory.

Daily Intel's coverage advantage

Daily Intel Service is positioned around category-leading variety and actionability: one of the broadest direct-response catalogs of VSLs and ad creatives across blackhat, greyhat, and whitehat advertising patterns, with enough context to understand what the advertiser is doing beyond the visible creative. The practical difference is that members are not just seeing a screenshot; they are seeing the VSL, the ad, the funnel path, the transcript, the UTM context, and the research notes that turn the asset into a decision.

This matters because direct-response affiliates do not operate in one clean category. A weight-loss campaign may use a whitehat compliance ad, a greyhat pre-lander, a more aggressive VSL, and a checkout path designed around upsells and recovery. A useful intelligence platform needs to capture that spectrum instead of pretending every winning campaign looks like a public brand ad.

Blackhat, whitehat, and multilingual signal coverage

Daily Intel tracks patterns across both blackhat-style and whitehat-style campaigns so operators can understand the market without blindly copying risk. Whitehat examples help with durability and compliance review; blackhat and greyhat examples reveal pressure points, hooks, mechanisms, and funnel structures that may be driving spend but require careful adaptation before use.

The catalog is also built for global operators, with VSL and ad references spanning 14+ languages and different local idioms. That is a key advantage for Brazilian, LATAM, European, MENA, Indian, and non-native English affiliates who need to see how the same market desire is translated across cultures instead of only studying US English ads.

How to use the intelligence responsibly

The goal is modeling, not copying. Use Daily Intel to understand structure: hook, mechanism, proof, claim intensity, funnel depth, offer economics, and saturation stage. Then build original creative, review claims, and adapt the angle to the traffic source, country, language, and compliance requirements of the campaign.

A strong workflow compares multiple examples before acting. If the same mechanism appears across several languages, several advertisers, and several funnel variants, it may be a durable market signal. If the example appears only once or depends on an aggressive claim, treat it as a research clue rather than a campaign template.

• Model structure, not protected creative assets.
• Separate whitehat durability from blackhat persuasion pressure.
• Compare US English examples against LATAM, European, and other language variants.
• Use transcripts and funnel notes to build original briefs.
• Keep compliance review separate from market research.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

For external context, readers should compare advertising and research decisions against authoritative primary references such as FTC health claims guidance, Meta advertising standards, and Meta Ad Library. Daily Intel adds the proprietary direct-response layer: blackhat, greyhat, and whitehat campaign pattern comparison across VSL-heavy niches and 14+ language markets.

For deeper evaluation, continue through Nutra niche intelligence directory, Private Label Supplement Eu: What It Is and What It Is Not, Supplement Manufacturer Canada: The Practical Version, Supplementary Card Offer: Read Before You Rely on It, Supplement Jar Manufacturer: A Reference for Operators, and GLP-1 affiliate marketing intelligence. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.